• Endocyte Inc., of West Lafayette, Ind., said an independent data safety monitoring board (DSMB) recommended continuation of combination therapy with investigational candidate vintafolide (MK-8109/EC145) and docetaxel as well as docetaxel as monotherapy in the Phase IIb TARGET trial, following a planned review of interim futility.